A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity (vol 138, pg 237, 2019)
A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity (Acta Neuropathologica, (2019), 138, 2, (237-250), 10.1007/s00401-019-02026-8)
Sven J. van der Lee (Vrije Universiteit Amsterdam)
Erik van den Akker (Leiden University Medical Center, TU Delft - Electrical Engineering, Mathematics and Computer Science, Molecular Epidemiology)
Najada Stringa (Amsterdam UMC)
Marc Hulsman (Vrije Universiteit Amsterdam, TU Delft - Electrical Engineering, Mathematics and Computer Science)
Niccolo Tesi (TU Delft - Electrical Engineering, Mathematics and Computer Science, Vrije Universiteit Amsterdam)
P. Alexopoulos
G. Rossi
J. van der Zee
Marcel J.T. Reinders (TU Delft - Electrical Engineering, Mathematics and Computer Science, Delft Bioinformatics Lab)
undefined More Authors (External organisation)
More Info
expand_more
Abstract
The IPDGC (The International Parkinson Disease Genomics Consortium) and EADB (Alzheimer Disease European DNA biobank) are listed correctly as an author to the article, however, they were incorrectly listed more than once.